|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin D: Globocan 2008: Cancer Incidence and
Mortality Worldwide: IARC Cancer Base No. 10. Lyon: pp. 1027–5614.
2008
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Tuncer M: Significance of Cancer in
Turkey, the Burden of Disease and Cancer Control Policies Cancer
Control in Turkey. 74. Onur Press, Health Ministry Publication;
Ankara: pp. 5–9. 2008
|
|
4
|
Statistical Analyses of National Breast
Cancer Registry Program of Turkish Federation of Breast Societies.
2008 Executive Summary of the National Cancer Control Programmes:
Policies and Managerial Guidelines. World Health Organization;
Geneva: 2002
|
|
5
|
Héry C, Ferlay J, Boniol M and Autier P:
Quantification of changes in breast cancer incidence and mortality
since 1990 in 35 countries with Caucasian-majority populations. Ann
Oncol. 19:1187–1194. 2008.PubMed/NCBI
|
|
6
|
Ruder EH1, Dorgan JF, Kranz S,
Kris-Etherton PM and Hartman TJ: Examining breast cancer growth and
lifestyle risk factors: early life, childhood, and adolescence.
Clin Breast Cancer. 8:334–342. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Setiawan VW, Monroe KR, Wilkens LR,
Kolonel LN, Pike MC and Henderson BE: Breast cancer risk factors
defined by estrogen and progesterone receptor status: the
multiethnic cohort study. Am J Epidemiol. 169:1251–1259. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin DB and Nelson PS: From genomics to
proteomics: techniques and applications in cancer research. Trends
Cell Biol. 11:S60–S65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhati A, Garg H, Gupta A, Chhabra H,
Kumari A and Patel T: Omics of cancer. Asian Pac J Cancer Prev.
13:4229–4233. 2012. View Article : Google Scholar
|
|
10
|
Dupont WD and Page DL: Risk factors for
breast cancer in women with proliferative disease. N Engl J Med.
312:146–151. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Collaborative Group on Hormonal Factors in
Breast Cancer. Breast cancer and hormonal contraceptives:
collaborative reanalysis of individual data on 53,297 women with
breast cancer and 100,239 women without breast cancer from 54
epidemiological studies. Lancet. 347:1713–1727. 1996. View Article : Google Scholar
|
|
12
|
Bièche I and Lidereau R: Genome-based and
transcriptome-based molecular classification of breast cancer. Curr
Opin Oncol. 23:93–99. 2011.PubMed/NCBI
|
|
13
|
Marcotte R and Muller WJ: Signal
transduction in transgenic mouse models of human breast cancer -
implications for human breast cancer. J Mammary Gland Biol
Neoplasia. 13:323–335. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
D’Alessio A, De Luca A, Maiello MR, Lamura
L, Rachiglio AM, Napolitano M, Gallo M and Normanno N: Effects of
the combined blockade of EGFR and ErbB-2 on signal transduction and
regulation of cell cycle regulatory proteins in breast cancer
cells. Breast Cancer Res Treat. 123:387–396. 2010.PubMed/NCBI
|
|
15
|
Reese DM and Slamon DJ: HER-2/neu
signal transduction in human breast and ovarian cancer. Stem Cells.
15:1–8. 1997.
|
|
16
|
Shen Q and Brown PH: Novel agents for the
prevention of breast cancer: targeting transcription factors and
signal transduction pathways. J Mammary Gland Biol Neoplasia.
8:45–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hyduke DR, Lewis NE and Palsson BØ:
Analysis of omics data with genome-scale models of metabolism. Mol
Biosyst. 9:167–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grundy SM and Vega GL: Role of
apolipoprotein levels in clinical practice. Arch Intern Med.
8:1579–1582. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nissen SE, Tsunoda T, Tuzcu EM,
Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS,
Grines CL, Halpern S, Crowe T, Blankenship JC and Kerensky R:
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in
patients with acute coronary syndromes: a randomized controlled
trial. JAMA. 290:2292–2300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moore RE, Navab M, Millar JS, Zimetti F,
Hama S, Rothblat GH and Rader DJ: Increased atherosclerosis in mice
lacking apolipoprotein A-I attributable to both impaired reverse
cholesterol transport and increased inflammation. Circ Res.
97:763–771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jahangiri A: High-density lipoprotein and
the acute phase response. Curr Opin Endocrinol Diabetes Obes.
17:156–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moore LE, Fung ET, McGuire M, Rabkin CC,
Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng XY and Pfeiffer
RM: Evaluation of apolipoprotein A1 and posttranslationally
modified forms of transthyretin as biomarkers for ovarian cancer
detection in an independent study population. Cancer Epidemiol
Biomarkers Prev. 15:1641–1646. 2006. View Article : Google Scholar
|
|
23
|
Kozak KR, Su F, Whitelegge JP, Faull K,
Reddy S and Farias-Eisner R: Characterization of serum biomarkers
for detection of early stage ovarian cancer. Proteomics.
5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ehmann M, Felix K, Hartmann D, Schnölzer
M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW and Friess H:
Identification of potential markers for the detection of pancreatic
cancer through comparative serum protein expression profiling.
Pancreas. 34:205–214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takaishi S and Wang TC: Gene expression
profiling in a mouse model of Helicobacter-induced gastric
cancer. Cancer Sci. 98:284–293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nosov V, Su F, Amneus M, Birrer M, Robins
T, Kotlerman J, Reddy S and Farias-Eisner R: Validation of serum
biomarkers for detection of early-stage ovarian cancer. Am J Obstet
Gynecol. 200:639.e1–639.e5. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hamrita B, Ben Nasr H, Gabbouj S,
Bouaouina N, Chouchane L and Chahed K: Apolipoprotein A1 −75 G/A
and +83 C/T polymorphisms: susceptibility and prognostic
implications in breast cancer. Mol Biol Rep. 38:1637–1643.
2011.
|
|
28
|
Lv GM, Li P, Wang WD, Wang ShK, Chen JF
and Gong YL: Lysophosphatidic acid (LPA) and endothelial
differentiation gene (Edg) receptors in human pancreatic cancer. J
Surg Oncol. 104:685–691. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Panupinthu N, Lee HY and Mills GB:
Lysophosphatidic acid production and action: critical new players
in breast cancer initiation and progression. Br J Cancer.
102:941–946. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zamanian-Daryoush M, Lindner D, Tallant
TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D,
Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD,
Finke J, DiDonato JA and Hazen SL: The cardioprotective protein
apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol
Chem. 288:21237–21252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hyka N, Dayer JM, Modoux C, Kohno T,
Edwards CK III, Roux-Lombard P and Burger D: Apolipoprotein A-I
inhibits the production of interleukin-1β and tumor necrosis
factor-α by blocking contact-mediated activation of monocytes by T
lymphocytes. Blood. 97:2381–2389. 2001.
|
|
32
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bendrik C, Robertson J, Gauldie J and
Dabrosin C: Gene transfer of matrix metalloproteinase-9 induces
tumor regression of breast cancer in vivo. Cancer Res.
68:3405–3412. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kato K, Hara A, Kuno T, et al: Matrix
metalloproteinases 2 and 9 in oral squamous cell carcinomas:
manifestation and localization of their activity. J Cancer Res Clin
Oncol. 131:340–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Galis ZS and Khatri JJ: Matrix
metalloproteinases in vascular remodeling and atherogenesis: the
good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
|
|
37
|
Holmbeck K, Bianco P, Caterina J, Yamada
S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I,
Ward JM and Birkedal-Hansen H: MT1-MMP-deficient mice develop
dwarfism, osteopenia, arthritis, and connective tissue disease due
to inadequate collagen turnover. Cell. 99:81–92. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Catania JM, Chen G and Parrish AR: Role of
matrix metalloproteinases in renal pathophysiologies. Am J Physiol
Renal Physiol. 292:F905–F911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Labrie M and St-Pierre Y: Epigenetic
regulation of mmp-9 gene expression. Cell Mol Life Sci.
70:3109–3124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hayden MS and Ghosh S: Shared principles
in NF-κB signaling. Cell. 132:344–362. 2008.
|
|
41
|
Sovak MA, Bellas RE, Kim DW, Zanieski GJ,
Rogers AE, Traish AM and Sonenshein GE: Aberrant nuclear
factor-kappaB/Rel expression and the pathogenesis of breast cancer.
J Clin Invest. 100:2952–2960. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nakshatri H and Goulet RJ Jr: NF-kappaB
and breast cancer. Curr Probl Cancer. 26:282–309. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Plummer SM, Holloway KA, Manson MM, Munks
RJ, Kaptein A, Farrow S and Howells L: Inhibition of
cyclo-oxygenase 2 expression in colon cells by the chemopreventive
agent curcumin involves inhibition of NF-κB activation via the
NIK/IKK signalling complex. Oncogene. 18:6013–6020. 1999.PubMed/NCBI
|
|
44
|
Barnes PJ and Karin M: Nuclear factor-κB:
a pivotal transcription factor in chronic inflammatory diseases. N
Engl J Med. 336:1066–1071. 1997.
|
|
45
|
Wertz IE, O’Rourke KM, Zhou H, Eby M,
Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A,
Koonin EV and Dixit VM: De-ubiquitination and ubiquitin ligase
domains of A20 downregulate NF-κB signalling. Nature. 430:694–699.
2004.PubMed/NCBI
|
|
46
|
Tolosano E and Altruda F: Hemopexin:
structure, function, and regulation. DNA Cell Biol. 21:297–306.
2002. View Article : Google Scholar
|
|
47
|
Kumar S and Bandyopadhyay U: Free heme
toxicity and its detoxification systems in human. Toxicol Lett.
157:175–188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tolosano E, Fagoonee S, Morello N, Vinchi
F and Fiorito V: Heme scavenging and the other facets of hemopexin.
Antioxid Redox Signal. 12:305–320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Balla J, Vercellotti GM, Jeney V, Yachie
A, Varga Z, Eaton JW and Balla G: Heme, heme oxygenase and ferritin
in vascular endothelial cell injury. Mol Nutr Food Res.
49:1030–1043. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Murrell TG: Epidemiological and
biochemical support for a theory on the cause and prevention of
breast cancer. Medical Hypotheses. 36:389–396. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ferris CD, Jaffrey SR, Sawa A, Takahashi
M, Brady SD, Barrow RK, Tysoe SA, Wolosker H, Barañano DE, Doré S,
Poss KD and Snyder SH: Haem oxygenase-1 prevents cell death by
regulating cellular iron. Nat Cell Biol. 1:152–157. 1999.PubMed/NCBI
|
|
52
|
Ho HY, Cheng ML and Chiu DT:
Glucose-6-phosphate dehydrogenase - from oxidative stress to
cellular functions and degenerative diseases. Redox Rep.
12:109–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bera TK, Zimonjic DB, Popescu NC,
Sathyanarayana BK, Kumar V, Lee BK and Pastan I: POTE, a
highly homologous gene family located on numerous chromosomes and
expressed in prostate, ovary, testis, placenta and prostate cancer.
Proc Natl Acad Sci USA. 99:16975–16980. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bera TK, Huynh N, Maeda H, Sathyanarayana
BK, Lee BK and Pastan I: Five POTE paralogs and their splice
variants are expressed in human prostate and encode proteins of
different lengths. Gene. 337:45–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu XF, Bera TK, Liu LJ and Pastan I: A
primate-specific POTE-actin fusion protein plays a role in
apoptosis. Apoptosis. 14:1237–1244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bera TK, Saint Fleur A, Ha D, Yamada M,
Lee Y, Lee B, Hahn Y, Kaufman DS, Pera M and Pastan I: Selective
POTE paralogs on chromosome 2 are expressed in human embryonic stem
cells. Stem Cells Dev. 17:325–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
